hlx43
mAbexperimentalADC
Clinical trial activity
13 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
12
Phase 3
0
Phase 4
0
Earliest trial started Nov 15, 2023 (NCT06115642)
Timeline
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colorectal Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Nasopharyngeal Carcinoma · Phase 2
- Neoplasms · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07269782 | Phase 2 | Jan 20, 2026 | Huazhong University of Science and Technology, Shanghai Henlius Biotech |
| NCT07253142 | Phase 2 | Jan 14, 2026 | Shanghai Henlius Biotech |
| NCT07301229 | Phase 2 | Dec 29, 2025 | Shanghai Henlius Biotech |
| NCT07115485 | Phase 2 | Sep 15, 2025 | Peking University, Shanghai Henlius Biotech |
| NCT07106892 | Phase 2 | Sep 15, 2025 | Shanghai Henlius Biotech |
| NCT06907615 | Phase 2 | Jun 9, 2025 | Chinese Academy of Medical Sciences, Icahn School of Medicine at Mount Sinai, Shanghai Henlius Biotech |
| NCT06857279 | Phase 2 | Apr 21, 2025 | Fudan University, Shandong first medical University, Shanghai Henlius Biotech |
| NCT06839066 | Phase 2 | Mar 31, 2025 | Shanghai Henlius Biotech |
| NCT06848699 | Phase 1/Phase 2 (Phase 2) | Feb 27, 2025 | Shanghai Henlius Biotech |
| NCT06769152 | Phase 2 | Feb 20, 2025 | Shandong University, Shanghai Henlius Biotech |
| NCT06742892 | Phase 2 | Feb 15, 2025 | Central South University, Shanghai Henlius Biotech |
| NCT06769113 | Phase 2 | Jan 26, 2025 | Shandong University, Shanghai Henlius Biotech |
| NCT06115642 | Phase 1 | Nov 15, 2023 | Chinese Academy of Medical Sciences, Shanghai Henlius Biotech |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Henlius Biotech | For profit | 13 | 13 | 2 | 2023 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 2 | 2023 |
| Shandong University | Academic/Hospital | 2 | 0 | 1 | 2025 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2026 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Shandong first medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
9 organizations
Page 1 / 1